Mark A. Rubin, MD

About Mark A. Rubin, MD

Dr. Mark A. Rubin is a professor of oncology and Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. Dr. Rubin is a recognized world leader in the area of prostate cancer genomics and pathology at Weill Cornell Medicine. He is a board-certified pathologist with expertise in prostate cancer pathology and the translation of novel findings to clinical investigations. As a laboratory-based researcher, He has more than 15 years of experience in biomarker discovery and characterization. He is currently Co-PI with Dr. Arul M. Chinnaiyan (University of Michigan) of a Biomarker Discovery Laboratory of the EDRN, and works closely with Dr. Levi Garraway (Broad Institute) on whole genome and exome sequencing of prostate cancer. In his role as a scientific leader at Weill Cornell Medicine, he is the Founding Director of the recently established Englander Institute for Precision Medicine.

His primary responsibility is for its scientific development and oversight for all genomics, computational cancer genomics, and biobanking activities related to the diagnosis and treatment of cancers. Among his seminal observations in prostate cancer genomics and biomarker development, he was the co-Senior Investigator of the first gene expression profiling study in prostate cancer (Nature, 2001) and the first whole genome and exome DNA sequencing studies in prostate cancer (Nature, 2011 and Nature Genetics, 2012). This work led to the discovery and development of several prostate cancer biomarkers, including AMACR, Hepsin, Pim1, EZH2, JAGGED1, SPOP, MED12, MYCN, and AURKA.